Insights
Search Results
Client Highlights
1.26.26
Wilson Sonsini Advises SR One on Corxel Pharmaceuticals $287 Million Series D
On January 22, 2026, Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cardiometabolic conditions around the world, announced the closing of a $287 million Series D financing. Wilson Sonsini Goodrich & Rosati advised investor SR One on the transaction.
Client Highlights
10.17.25
Wilson Sonsini Advises SR One on Veradermics' Oversubscribed Series C
On October 15, 2025, Veradermics, a dermatologist-founded, late clinical-stage biopharmaceutical company developing therapeutics for common dermatologic conditions, announced the completion of an oversubscribed $150 million Series C financing. SR One led the funding round, with participation from new investors Viking Global Investors, Marshall Wace, Invus, funds managed by abrdn Inc., Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, and current investors including Longitude Capital, Suvretta Capital Management, Surveyor Capital, and other undisclosed investors. Wilson Sonsini Goodrich & Rosati advised lead investor SR One on the transaction.
Client Highlights
10.15.25
Firm Advises Sofinnova, Novo Holdings, and Forbion on Expedition Therapeutics’ $165 Million Series A Financing
On October 9, 2025, Expedition Therapeutics, a biotech company developing therapies for novel inflammatory and respiratory diseases, announced the closing of an oversubscribed $165 million Series A financing. The round was co-led by Sofinnova Investments and Novo Holdings, with additional investment from Forbion, Dawn Biopharma, Adage, Balyasny, Logos Capital, Sanofi Ventures, and existing investors BVF Partners and Venrock Healthcare Capital Partners. Wilson Sonsini Goodrich & Rosati advised co-lead investors Sofinnova and Novo Holdings, as well as syndicate investor Forbion, on the transaction.
Client Highlights
7.30.25
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
The Wilson Sonsini team advising ImmunityBio includes:
Corporate
Patents and Innovations
For more information, please see ImmunityBio’s press release.
Client Highlights
7.01.25
Wilson Sonsini Advises Celltrio on $15 Million Financial Investment
On June 17, 2025, Celltrio, a pioneering life sciences company delivering advanced automation solutions for cell culturing and cell and gene therapy, announced the closing of a $15 million financial investment round led by Premier Partners, a leading investor in healthcare innovation. Wilson Sonsini Goodrich & Rosati advised Celltrio on the transaction.
The new funding will accelerate the global commercialization of RoboCell®, Celltrio’s flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities; expand commercial operations across North America, Europe, and Asia; and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories.
The Wilson Sonsini team that advised Celltrio on the transaction included:
Corporate
Ben Capps
Dani Glazer Signaigo
James Keegan
Regulatory
Nimit Dhir
Jahna Hartwig
For more information, please see Celltrio’s news release.
The new funding will accelerate the global commercialization of RoboCell®, Celltrio’s flagship modular platform for fully automated, sterile cell culturing and cell therapy manufacturing. Investment proceeds will be used to scale manufacturing capabilities; expand commercial operations across North America, Europe, and Asia; and fuel continued innovation of GMP-ready automation solutions for biopharma, regenerative medicine, and advanced research laboratories.
The Wilson Sonsini team that advised Celltrio on the transaction included:
Corporate
Ben Capps
Dani Glazer Signaigo
James Keegan
Regulatory
Nimit Dhir
Jahna Hartwig
For more information, please see Celltrio’s news release.
Client Highlights
2.19.25
Firm Advises Novo Holdings on Investment in Newleos Therapeutics’ $93.5 Million Series A
On February 13, 2025, Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, announced the closing of an oversubscribed $93.5 million Series A financing. The financing was led by Goldman Sachs Alternatives with participation from Novo Holdings A/S, Longwood Fund, DCVC Bio, and Arkin Bio Capital. Wilson Sonsini advised Novo Holdings A/S on the transaction.
Client Highlights
10.22.24
Wilson Sonsini Advises Novo Holdings and F-Prime Capital on AvenCell’s $112 Million Series B
On October 22, 2024, AvenCell Therapeutics, a leading clinical-stage cell therapy company focused on advancing both autologous and allogeneic switchable CAR-T cell therapies, announced that it has raised $112 million in Series B financing. The financing was led by global life sciences investor Novo Holdings. New investors F-Prime Capital, Eight Roads Ventures Japan, Piper Heartland Healthcare Capital, and NYBC Ventures also participated in the round alongside founding investor Blackstone Life Sciences. Wilson Sonsini Goodrich & Rosati advised Novo Holdings and F-Prime Capital on the transaction.
Client Highlights
1.26.23
Firm Advises Pacific Biosciences of California on Upsized Stock Offering
On January 24, 2023, life sciences technology company Pacific Biosciences of California Inc announced that it has priced a 17.5 million share secondary stock offering at $10 per share. The transaction will raise $175 million, which was upsized from the original size of $150 million. Wilson Sonsini Goodrich & Rosati advised Pacific Biosciences on the transaction.